| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
13.00(B) |
| Last
Volume: |
1,143,139 |
Avg
Vol: |
421,691 |
| 52
Week Range: |
$210.76 - $276.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
576,795 |
633,480 |
690,363 |
1,841,548 |
| Total Sell Value |
$141,127,434 |
$154,067,329 |
$166,940,864 |
$453,181,711 |
| Total People Sold |
8 |
8 |
8 |
10 |
| Total Sell Transactions |
72 |
83 |
94 |
262 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-10 |
4 |
AS |
$257.73 |
$2,092,043 |
D/D |
(8,000) |
130 |
|
-16% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-10 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
AS |
$262.09 |
$2,115,602 |
D/D |
(8,000) |
130 |
|
-18% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-09 |
4 |
AS |
$263.93 |
$84,456 |
D/D |
(320) |
524 |
|
-18% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-08 |
4 |
AS |
$261.21 |
$2,017,508 |
D/D |
(7,680) |
130 |
|
-19% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-08 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Olian Judy D. |
|
– • – |
2022-11-08 |
4 |
S |
$265.09 |
$159,054 |
D/D |
(600) |
8,665 |
|
19% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-07 |
4 |
AS |
$263.52 |
$2,140,871 |
D/D |
(8,000) |
130 |
|
-17% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-07 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2022-11-07 |
4 |
D |
$266.80 |
$1,977,255 |
D/D |
(7,411) |
1,384 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2022-11-07 |
4 |
OE |
$52.12 |
$489,549 |
D/D |
7,411 |
3,795 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-11-07 |
4 |
D |
$266.80 |
$1,334,000 |
D/D |
(5,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2022-11-07 |
4 |
OE |
$88.03 |
$440,150 |
D/D |
5,000 |
5,000 |
|
- |
|
| Olian Judy D. |
|
– • – |
2022-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,125 |
9,265 |
|
- |
|
| Mesa Nilda |
|
– • – |
2022-11-07 |
4 |
S |
$268.57 |
$77,886 |
D/D |
(290) |
6,180 |
|
17% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-04 |
4 |
AS |
$262.84 |
$2,118,802 |
D/D |
(8,000) |
130 |
|
-15% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-04 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-11-03 |
4 |
AS |
$254.12 |
$1,542,494 |
D/D |
(6,000) |
36,397 |
|
-17% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2022-11-03 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,397 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-03 |
4 |
AS |
$255.01 |
$2,111,701 |
D/D |
(8,000) |
130 |
|
-17% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-03 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Causey Christopher |
|
– • – |
2022-11-03 |
4 |
AS |
$260.00 |
$650,000 |
D/D |
(2,500) |
2,835 |
|
-17% |
|
| Causey Christopher |
|
– • – |
2022-11-03 |
4 |
OE |
$175.43 |
$438,575 |
D/D |
2,500 |
5,335 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2022-11-02 |
4 |
AS |
$236.01 |
$1,997,944 |
D/D |
(8,000) |
130 |
|
-13% |
|
5060 Records found
|
|
Page 22 of 203 |
|
|
4.68 (1.73%) 
